<DOC>
	<DOCNO>NCT01204359</DOCNO>
	<brief_summary>Iodine 131 ( 131Iï¼‰ treatment Graves disease Graves ophthalmopathy relationship always focus debate . Majority view current treatment increase 131I Graves ophthalmopathy , therefore , Graves disease associate exophthalmos contraindication 131I treatment . While treatment corticosteroid , timely corrective measure effective prevent Graves ophthalmopathy adverse effect . But merger severe proptosis patient Graves , especially infiltrative exophthalmos , application 131I treatment induce aggravate yet reach consensus , , 131I treatment still careful , mainly due plaque prospective study visual assessment lack uniform standard , variety factor ( include smoking , work status , 131I treatment thyroid dos , etc . ) may also interfere influence ultimate effect 131I Graves ophthalmopathy . In view situation Graves disease patient Graves ophthalmopathy could 131I treatment , dose adjustment , use require treatment systemic issue research , explore treatment exophthalmos reduction mitigation increase proptosis reasonable treatment symptom . To promote standardization 131I treatment Graves disease basis .</brief_summary>
	<brief_title>The Prospective Study Standard Treatment Graves Disease Iodine 131 Prevention Adverse Reactions</brief_title>
	<detailed_description>description</detailed_description>
	<mesh_term>Hypothyroidism</mesh_term>
	<mesh_term>Exophthalmos</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>typical clinical symptom Graves disease , diffuse goiter , eye sign ( include exophthalmos ) , thyroid function ( FT3 , FT4 , rTSH ) thyroid autoantibody image examination confirm . 131I treatment contraindication , sign informed consent , failure complete treatment followup estimate patient patient suitable radionuclide therapy</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>